Finally, we outline the implications of adopting semaglutide as a disease-modifying agent in MASH with F2-F3 fibrosis, note the study limitations and remaining questions, and argue that combinatorial approaches targeting complementary metabolic and hepatocentric pathways may define the next phase of MASLD management
Crucially, the pill requires no restrictions around timing or food and water intake
Light exercise like walking, yoga, or swimming paradoxically boosts energy during semaglutide treatment by improving circulation and metabolic efficiency
Tirzepatide (Mounjaro): A dual GIP/GLP-1 receptor agonist with MHRA approval for type 2 diabetes and, more recently, for weight management in adults with obesity or overweight with weight-related comorbidities
No fad diets, just real results
Hepatotoxicity risk assessment: Sustained-release versus immediate-release niacin formulations